

Targeted disruption of gene function in *Drosophila* by RNA interference (RNA-i): A role for *nautilus* in embryonic somatic muscle formation

(myogenesis/founder cells)

LEONIE MISQUITTA AND BRUCE M. PATERSON*

Laboratory of Biochemistry, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892

Communicated by Maxine F. Singer, Carnegie Institution of Washington, Washington, DC, December 24, 1998 (received for review November 12, 1998)

ABSTRACT The expression of the MyoD gene homolog, *nautilus* (*nau*), in the *Drosophila* embryo defines a subset of mesodermal cells known as the muscle “pioneer” or “founder” cells. These cells are thought to establish the future muscle pattern in each hemisegment. Founders appear to recruit fusion-competent mesodermal cells to establish a particular muscle fiber type. In support of this concept every somatic muscle in the embryo is associated with one or more *nautilus*-positive cells. However, because of the lack of known (isolated) *nautilus* mutations, no direct test of the founder cell hypothesis has been possible. We now have utilized toxin ablation and genetic interference by double-stranded RNA (RNA interference or RNA-i) to determine both the role of the *nautilus*-expressing cells and the *nautilus* gene, respectively, in embryonic muscle formation. In the absence of *nautilus*-expressing cells muscle formation is severely disrupted or absent. A similar phenotype is observed with the elimination of the *nautilus* gene product by genetic interference upon injection of *nautilus* double-stranded RNA. These results define a crucial role for *nautilus* in embryonic muscle formation. The application of RNA interference to a variety of known *Drosophila* mutations as controls gave phenotypes essentially indistinguishable from the original mutation. RNA-i provides a powerful approach for the targeted disruption of a given genetic function in *Drosophila*.

The role of specific genes during development traditionally is determined by selecting or creating a mutation in the gene of interest followed by detailed analysis of the phenotype. Because there is no targeted homologous recombination in *Drosophila* to allow “knock-out” or gene-replacement strategies, mutations usually are obtained by a combination of genetic selection, P element insertion, and deficiency analysis after γ -irradiation. These methods are very labor-intensive and time-consuming and, on occasion, do not yield a clear answer.

We have been studying the role of the *Drosophila* MyoD homolog, *nautilus*, in the formation of embryonic muscle. Previous studies in *Drosophila* and grasshopper have suggested that particular sets of muscle precursor cells establish a muscle prepattern in each hemisegment and then recruit fusion-competent mesodermal cells to build the characteristic muscle groupings (1–3). This is known as the muscle “founder” or muscle “pioneer” theory of muscle formation. In *Drosophila* the *nautilus*-expressing cells are thought to be the muscle “founder cells.” Currently, no point mutations exist for the gene, although deficiencies have been characterized that are reported to eliminate *nautilus* (4–6). In the absence of a mutation in *nautilus*, two alternative strategies were employed

to determine its role in myogenesis. First, we used the specificity of the *nautilus* promoter to target *gal4*-activated ricin toxin expression (7, 8) only in *nautilus*-positive cells (9), and, second, *nautilus* double-stranded RNA (dsRNA) was injected into embryos to genetically interfere with gene function, as reported previously in studies with *Caenorhabditis elegans* (10). Our goal was to determine the role of the “founder” cells in *Drosophila* embryo myogenesis and to investigate the direct role of *nautilus* in embryonic muscle formation.

Studies in *C. elegans* have demonstrated elegantly that the introduction of dsRNA corresponding to either a portion or the entire coding region of a particular gene into embryonic cells can interfere with the function of the endogenous gene to give a phenotype essentially equivalent to the known genetic mutation (10). Furthermore, injection into the adult resulted in genetic interference in the next generation of worms. This dsRNA interference (RNA-i) with genetic function was substantially more effective than the injection of either RNA strand alone. Surprisingly, the results strongly suggested that dsRNA was acting catalytically. The application of this method to *Drosophila* is demonstrated here in the analysis of *nautilus* function during muscle formation in the embryo. The general utility of RNA-i in the analysis of gene function during *Drosophila* development is demonstrated by the injection of dsRNAs representing a panel of genes expressed at various embryonic stages. The mutant phenotype was observed for essentially all genes tested.

MATERIALS AND METHODS

Preparation of dsRNA for Injection. Sequences to be expressed as dsRNA were cloned into Bluescript KS(+), linearized with the appropriate restriction enzymes, and transcribed *in vitro* with the Ambion T3 and T7 Megascript kits following the manufacturer’s instructions. Transcripts were annealed in injection buffer (0.1 mM NaPO₄, pH 7.8/5 mM KCl) after heating to 85°C and cooling to room temperature over a 1- to 24-hr period. All annealed transcripts were analyzed on agarose gels with DNA markers to confirm the size of the annealed RNA and quantitated as described previously (10). Injected RNA was not gel-purified because the efficacy was the same. We estimate that the injection of 0.1 nl of a 0.1- to 1.0-mg/ml solution of a 1-kb dsRNA corresponds to roughly 10⁷ molecules. Sources for the DNA clones were as follows: *nautilus* (9), *twist* (11), *daughterless* (12, 13), *engrailed* (14), *S59* (15), *DMEF2* (16), β -galactosidase, and *white* (17).

Toxin Ablation System and Antisense Expression. The targeted ablation strategy using controlled expression of wild-

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

PNAS is available online at www.pnas.org.

Abbreviations: dsRNA, double-stranded RNA; bHLH, basic helix-loop-helix; CNS, central nervous system; PNS, peripheral nervous system.

*To whom reprint requests should be addressed. e-mail: bruce@sunspot.nci.nih.gov.

type ricin was developed by A. Brand (7, 8). Stocks of the UAS-ricin A gene flies were kindly provided by A. Brand. Briefly, to prevent transient expression of ricin toxin after injection, the *white* gene is inserted between the *gal4*UAS and the ricin A coding sequence and is flanked by *flp* recombinase target sites. Heat-shock *flp* recombinase is introduced by genetic cross. The UAS-ricin is balanced over CyO marked by *en-lacZ* at the *wingless* locus. The heat-shock *flp* line was injected with the *gal4* P element driven by the 8.5-kb *nautilus* promoter that specifically expresses *gal4* only in *nautilus*-positive cells at all stages of development, as described previously (9). To express *nautilus* antisense RNA in embryos only the coding region of *nautilus* was inserted in reverse orientation into the *gal4* UAS plasmid and injected into embryos to produce the transgene stock (18). Four independent lines were established by standard procedures. Antisense expression was induced by crossing the *gal4* UAS antisense *nautilus* line with the *gal4* enhancer trap line 24B/twist *gal4* that expresses high levels of *gal4* from the twist promoter and the mesoderm-restricted enhancer trap line 24B (18, 19).

Injection of Embryos Through the Chorion. Cages were set up using 2- to 4-day-old yw 67c flies. Agar-grape juice plates were alternated every hour to synchronize the egg collection for 1–2 days. The eggs were collected over a 30- to 60-min period for subsequent injection. The eggs were washed into a nylon mesh basket with tap water. Eggs were lined up anterior to posterior directly onto a glass slide. The eggs were injected in the posterior end slightly off-center using an Eppendorf transjector. After injection, slides were stored in a moist chamber to prevent drying out the embryos. The *S59 lacZ* line used for injections of *S59* dsRNA was from M. Frasch (unpublished data).

General Methods. Antibody stainings, β -galactosidase assays, and cuticle preparations were done following standard procedures and as described previously (9).

RESULTS

Requirement for *nautilus*-Expressing Cells in *Drosophila* Embryonic Muscle Formation. We first investigated the specific ablation of *nautilus*-expressing cells by taking advantage of the *gal4*/UAS system to express wild-type ricin toxin in *nautilus*-positive embryonic cells (7, 8, 18, 19). We have shown previously that an 8.5-kb *nautilus* promoter fragment will drive *lacZ* expression specifically in the *nautilus*-positive embryonic cells to mimic the endogenous protein pattern (9). No ectopic expression was observed. This promoter fragment was used to express *gal4* in the UAS ricin system. Activation of the wild-type ricin A chain is regulated by an *flp* cassette containing the *white* gene to block any toxin expression unless *white* is removed by heat-shock-activated *flp* recombinase. The ricin A fragment used in this system cannot cross cell membranes once it is released from ablated cells because it is missing the domain necessary to enter cells.

Flies expressing heat-shock FLPase that were also homozygous for a P element containing the *nautilus* promoter driving *gal4* were crossed with flies carrying the UAS ricin cassette over a *lacZ engrailed* marker. Embryos were collected and heat-shocked 2 hr after egg laying to activate ricin expression in *nautilus*-positive cells. At various time points after heat shock embryos were fixed and analyzed for myosin and *lacZ* expression. Non-heat-shocked embryos were stained as controls for the normal muscle pattern by using myosin heavy chain antibody (9). Embryos not expressing ricin were marked by *lacZ* expression. The muscle pattern in all embryos expressing ricin was extremely disrupted (Fig. 1 B and C) whereas the control non-heat-shocked embryos had a normal embryonic muscle pattern (Fig. 1A). From the ricin toxin ablation experiments we conclude that the *nautilus*-expressing cells in the embryo are essential for muscle pattern formation, consistent

with their role as muscle “founder” cells. The remaining mesodermal cells are unable to build and organize any muscle pattern in the absence of the *nautilus*-expressing cells. The variation in the ablation phenotype we observed is likely a result of the stage of muscle development at the time of ricin induction. Heat shock in larval instar stages also resulted in lethality (data not shown), implying that *nautilus* also plays a role in later *Drosophila* development, but we have not yet analyzed the pattern of muscle expression in these instances.

Disruption of the *Drosophila* Embryonic Muscle Pattern with the Expression of *nautilus* Antisense RNA in the Embryo. “Knock-outs” and mutant screens in the mouse and *C. elegans*, respectively, have shown that MyoD-related proteins play a crucial role in myogenesis in these organisms (20, 21). To test whether the direct ablation of *nautilus* mRNA would result in a disrupted muscle phenotype in the *Drosophila* embryo, the *gal4*/UAS system was used to express *nautilus* antisense RNA throughout the mesoderm (18, 19). Females from the *gal4* enhancer trap line 24B containing the *twi-gal4* transgene were crossed with males from four independent lines homozygous for a *gal4* UAS antisense *nautilus* transgene containing only the coding region in reverse orientation. The degree of disruption in the muscle pattern of the progeny flies depended partially on the particular antisense transgenic line used in the cross, as shown for three of these lines (Fig. 1 D–F). Previous studies with the overexpression of *nautilus* gave a phenotype that included the formation of some additional muscles and a disruption of the heart tube, presumably because of the formation of skeletal muscle cells in the heart tube itself (22). With the additional results from the antisense induction experiments we conclude that *nautilus* plays a major role in the formation of the muscle pattern and may be involved in the determination of the muscle “founder” cell lineage in the embryo, because the muscle phenotypes resulting from the ricin ablation of the *nautilus*-positive cells and the *nautilus* antisense expression were so similar.

Severe Disruption of the Muscle Pattern in the Embryo with the Injection of *nautilus* dsRNA. Given the remarkable results obtained with the RNA interference studies in *C. elegans* (10), we decided to try the same approach in *Drosophila*, specifically addressing the question of *nautilus* function in embryonic muscle formation. To facilitate the rapid injection of 300–500 embryos for each dsRNA tested and the subsequent analysis of the mutant phenotypes, we developed methods to inject dsRNA directly through the chorion of the embryo. Our initial tests with full-length *nautilus* dsRNA gave a very severe pattern of muscle disruption (Fig. 1 G and H) and looked similar to the toxin ablation phenotype. Injection of either buffer alone or sodium azide gave no disruption of the muscle pattern (Table 1). To control for the specificity of the muscle pattern disruption, we injected *nautilus* dsRNA into a previously described transgenic line 14.1 in which the *nautilus* promoter drives *lacZ* expression in the founder cells and newly formed embryonic muscles (Fig. 1M) (9). Injection of *nautilus* dsRNA resulted in a severely disrupted blue muscle pattern (Fig. 1N) whereas injection of β -galactosidase dsRNA eliminated *lacZ* expression without any disruption in the muscle pattern (data not shown, but identical to Fig. 1A). Furthermore, the pattern of DMEF2 expression (23) essentially was normal in embryos injected with *nautilus* dsRNA (data not shown). Thus, the disruption of the muscle pattern observed depended on *nautilus* dsRNA.

It was formally possible that dsRNA representing the highly conserved basic helix–loop–helix (bHLH) domain in *nautilus* was acting nonspecifically with mRNA for another bHLH protein to disrupt the muscle pattern. This idea was used to explain the additional mutant phenotype observed with the injection of dsRNA encoding a conserved domain from the *unc54C* gene in *C. elegans* RNA-i studies (10). To address this possibility, we prepared dsRNAs representing the amino ter-




FIG. 1. Muscle formation and gene expression patterns in the *Drosophila* embryo as modulated by specific cell ablation, antisense expression, and RNA interference by the injection of dsRNA. Ablation of the *nautilus*-positive muscle founder cells by ricin toxin disrupts muscle formation. (A) Ricin not induced. (B and C) Ricin induced in *nautilus*-positive cells. Antisense expression of *nautilus* RNA disrupts muscle formation in three different UAS antisense (AS) *nautilus* lines (D–F). Injection of *nautilus* dsRNA blocks muscle formation (G and H) and does not depend on the bHLH domain for the disruption [dsRNA for the C terminus (I), dsRNA for the bHLH domain (J), and dsRNA for the amino terminus of *nautilus* (K)]. Injection of β -galactosidase dsRNA does not disrupt the muscle pattern but eliminates normal lacZ expression (shown in M) without affecting muscle pattern (similar to A), whereas injection of *nautilus* dsRNA into a *nautilus* lacZ line 14.1 disrupts the lacZ muscle pattern (compare M and N) and reduces lacZ expression. Injection of dsRNA for *DMEF2* [uninjected (L) and injected (O)], *S59* [uninjected (P) and injected (Q)], *daughterless* [uninjected (R) and injected (S); C, CNS; P, PNS], and *white* [uninjected (T) (w+) and injected (U)] results in the disruption of gene function for these genes. A–L and O–Q were stained with antimyosin; M and N were stained with 5-bromo-4-chloro-3-indolyl β -D-galactoside; R and S were stained with monoclonal 22C10 and horseradish peroxidase for CNS and PNS. AS in the upper left-hand corner marks the *nautilus* antisense lines, -U indicates the uninjected phenotype for the designated gene, and -I indicates dsRNA injection for the indicated gene.

Table 1. Analysis of gene expression patterns using RNA interference

Phenotype injected	RNA hybrid used	Known expression/mutant phenotype	Resulting phenotype	% of mutants
yw ^{67c}	Mook-injected buffer + dye	Wild-type MHC	Wild-type MHC	0
yw ^{67c}	Sodium azide	Unknown, should have a wild-type MHC	Wild-type MHC	0
yw ^{67c}	<i>twist</i>	Twisted embryos with marginal cuticular phenotype	Twisted embryos with marginal cuticular phenotype	86
yw ^{67c}	<i>engrailed</i>	Merged denticular bands, lawn of cuticle	Merged denticular bands, lawn of cuticle	79
yw ^{67c}	<i>Mef2</i>	No muscle	No muscle	72
S59- β -gal	<i>S59</i>	Muscles 18 and 25 absent	Muscles 18 and 25 absent	75
yw ^{67c}	<i>daughterless</i>	Most of the PNS absent; partly disrupted CNS	Most of the PNS absent; partly disrupted DNS	85
yw ^{67c}	<i>nautilus</i>	Mutant phenotype unknown	Disrupted muscle pattern; CNS and PNS normal	76
yw ^{67c}	3' Nautilus domain	Mutant phenotype unknown	Disrupted muscle pattern	78
yw ^{67c}	5' Nautilus domain	Mutant phenotype unknown	Disrupted muscle pattern	76
yw ^{67c}	bHLH domain	Mutant phenotype unknown	Disrupted muscle pattern	74
nau- β -gal	<i>nautilus</i>	Nautilus β -gal expression pattern	Disrupted β -gal muscle pattern	80
nau- β -gal	β -gal	Nautilus β -gal expression pattern	β -gal expression absent; wild-type MHC pattern	80

MHC, major histocompatibility complex; β -gal, β -galactosidase.

minus (amino acids 1–147), the bHLH domain (amino acids 148–214), and the carboxyl terminus (amino acids 215–end) of *nautilus* for injection. All three domains produced a severe disruption of the muscle pattern (C terminus, bHLH domain, and amino terminus, Fig. 1 I–K, respectively), ruling out the nonspecific interaction of the *nautilus* bHLH dsRNA as a reason for the interference phenotype initially observed with full-length *nautilus* dsRNA.

RNA Interference and the Study of Gene Function in *Drosophila*. The results from the injection of *nautilus* dsRNA pointed to a more general approach for the analysis of gene function during *Drosophila* development and suggested that the RNA interference method essentially would mimic a gene “knock-out” in the injected generation of *Drosophila* embryos. To test this idea we obtained a variety of cDNA clones representing a maternal gene expressed in the embryo (*daughterless*), additional genes involved in myogenesis (*S59*, *DMEF2*), homeobox genes (*engrailed* and *S59*), a gene important for gastrulation (*twist*), and a gene expressed in the adult eye (*white*). This panel of genes covers most stages of *Drosophila* development.

We initially tested *twist* because the mutant has a clear phenotype that is easy to score compared with the wild-type larva (Fig. 2A). The injection of *twist* dsRNA (the complete coding region) into embryos produced a twisted larval phenotype that was indistinguishable from the original *twist* mutation (Fig. 2B, *twi* 1096 mutant compared with the injected embryo in Fig. 2C). Similarly, injection of the first 1,200 bp of *engrailed* dsRNA produced the compressed denticular belt pattern characteristic of an *engrailed* null mutant (*enIIB86*) (Fig. 2D, *en* mutant compared with the injected embryo in Fig. 2E). *Daughterless* mRNA is both maternally loaded and expressed zygotically, and the mutant phenotype produces very characteristic disruptions in the central nervous system (CNS) and peripheral nervous system (PNS) (12, 13). It has been shown previously that *mex3*, a maternally loaded RNA in *C. elegans*, can be ablated by dsRNA injection into the gonads (10). We injected *daughterless* dsRNA (complete coding region) and looked for the characteristic neuronal phenotypes by using the mAb MAB 22C10 (12). The CNS as well as the PNS were disrupted to varying degrees in the injected embryos (Fig. 1S) compared with the uninjected embryos (Fig. 1R). The severity of the phenotype consistently showed a CNS disruption with a variable PNS pattern, possibly reflecting the fact that the CNS is formed before the PNS. This result suggested maternally loaded as well as zygotically expressed RNA can be affected by RNA-i in *Drosophila*. The homeobox gene *S59*

marks a subset of muscle founder cells for 5 of 29 muscles in each hemisegment of the embryo corresponding to muscles 5, 18, 25, 26, and 27 (15). Embryos with an *S59 lacZ* transgene marking muscles 18 and 25 (from M. Frasch) were injected with *S59* dsRNA (complete coding region). The *S59*-specific *lacZ* antibody-staining pattern was abolished (data not shown). The total muscle pattern for embryos injected with *S59* dsRNA (Fig. 1Q, injected embryos; Fig. 1P, uninjected embryos), although disrupted, still shows the presence of poorly organized muscle groups in each hemisegment. This is unlike the almost complete absence of muscle observed with the injection of *nautilus* dsRNA (Fig. 1G and H). *DMEF2*, a member of the MADS domain transcription factor family, is essential for muscle formation in *Drosophila* (23). The *DMEF2* $-/-$ embryo has no muscle and is missing the characteristic




FIG. 2. Cuticular patterns in early larvae induced by injection of *twist* and *engrailed* dsRNAs. (A) Wild-type cuticular pattern for early larva. (B) *Twist* phenotype of the known *twist* mutation *twi*¹⁰⁹⁶. (C) Embryos injected with *twist* dsRNA show the same phenotype as in B. (D) Fused cuticular band phenotype seen for *enIIB86* null mutants. (E) Embryos injected with the *engrailed* dsRNA show the same *en* null phenotype as in D.

gut constrictions found in the uninjected embryo (Fig. 1L). Injection of *DMEF2* dsRNA (complete coding region) resulted in embryos lacking any detectable muscle and an absence of gut morphology (Fig. 1O).

Because particular RNA interference phenotypes were transferable to the next generation of *C. elegans* (10), we were particularly interested to see whether genes expressed in the adult eye could be affected by the injection of dsRNA into the embryo. We chose to look at the *white* gene, even though it is expressed throughout embryogenesis, and asked if any aspect of the white-eyed mutant phenotype could be observed after the injection of *white* dsRNA (the first 500 bp from the P element minigene) into wild-type embryos with red eyes. Phenotypes indicating interference with *white* gene function were observed in response to the RNA interference with *white* dsRNA (Fig. 1T, injected embryo; Fig. 1U, uninjected embryo), although the frequency of the mutant phenotype was extremely low (<3%) compared with the level of typical mutant phenotypes scored in the embryos injected with dsRNA (>75%). Similar to the results reported in *C. elegans*, very few molecules of *white* dsRNA appear to be required to obtain some evidence of interference with *white* gene function in the adult eye because we are injecting only on the order of 10^7 molecules. This last result supports the idea that RNA interference is acting catalytically because the transition from embryo to adult fly would substantially dilute the injected dsRNA. A summary of the phenotypes observed is given in Table 1.

DISCUSSION

Nautilus Is Required to Form Embryonic Muscle. Unlike vertebrate myogenesis, where all skeletal muscle precursor cells express members of the MyoD family of regulatory proteins (21, 24), *Drosophila* muscle development involves two distinct cell types (1, 2, 6). One set of cells, denoted as the founder cells, is marked by the expression of the MyoD homolog, *nautilus*, and is thought to establish the muscle pattern in each hemisegment of the embryo. These cells then fuse with a second, uncommitted mesodermal cell population to build the muscle fiber pattern. Support for this idea comes from initial studies in the grasshopper where morphologically distinct mononucleated mesodermal cells, termed muscle "pioneers," eliminate muscle formation when laser-ablated in the embryo (3). It is not known, however, whether the grasshopper muscle "pioneer" cells express MyoD because the homolog has not been isolated. Morphological examination of myogenesis in *Drosophila* has suggested a similar process is occurring, but it has not been directly demonstrated (1, 2).

The toxin ablation strategy (7, 8) has allowed us to eliminate specifically the *nautilus*-expressing cells and determine their role in myogenesis in the *Drosophila* embryo. The founder cell hypothesis predicts that loss of these cells should eliminate the muscle pattern and the formation of most muscle by the uncommitted mesodermal cells, and this is what was observed. This toxin strategy, developed to study the role of glial cells in axon tract formation, allowed the ablation of a selected population of glial cells in the *Drosophila* embryonic nervous system in a cell-autonomous manner and depended on only the targeted expression of *gal4* through the appropriate promoter (8). Use of the *nautilus* promoter fragment to drive *gal4* expression specifically and only in the *nautilus*-expressing mesodermal cells provided the same specificity in the ablation of these cells in the embryo (9).

Deficiencies have been reported that are thought to remove the *nautilus* gene with little effect on muscle pattern formation or viability (5, 6). This was interpreted to mean *nautilus* is not required for the formation of muscle precursors, but rather plays a role in their differentiation into mature fibers. Furthermore, *nautilus* was suggested to function in a subset of

muscle precursors to implement their specific differentiation. Although the induction of antisense *nautilus* RNA with the *gal4/UAS* system produced a disruption of the muscle pattern, somewhat dependent on the antisense transgene line used, genetic interference through the injection of *nautilus* dsRNA completely eliminated the normal formation of the muscle groups. The myosin staining pattern was very similar to the one observed with the most severe ricin toxin ablation of the *nautilus*-expressing cells. These combined results suggest that *nautilus* expression defines the founder cell population and plays an essential role in myogenesis in the *Drosophila* embryo. The reasons for the discrepancy between our results and those published for the deficiencies reported to eliminate *nautilus* are not clear (6). However, the possible maternal contribution of *nautilus* was not ruled out completely. The cDNA probe used to determine the absence of the *nautilus*-coding region in the deficiency corresponded to the C terminus of *nautilus* and did not represent either the bHLH or amino-terminal portions of the protein. Therefore, it is theoretically possible that the deficiency still expresses a partially functional, truncated *nautilus* protein that could account for the minor nonlethal phenotype observed.

Genetic Interference by the Injection of dsRNA in *Drosophila*. The severe muscle disruption phenotype observed with the injection of *nautilus* dsRNA representing the entire coding region gave us concern about the specificity of the interference. Because the bHLH domain is common to many regulatory proteins in *Drosophila*, including *twist* and *daughterless*, we injected dsRNA representing domains in *nautilus* outside the bHLH region. dsRNAs encoding regions of *nautilus* that do not contain the bHLH domain gave phenotypes essentially indistinguishable from that observed with the injection of the dsRNA for the entire coding region. This clearly demonstrated that the RNA interference phenotype observed for *nautilus* was specific and not a result of any homologous domain effect. This was supported further by the injection of dsRNA for β -galactosidase into the *nautilus* promoter-lacZ transgenic line 14.1 that expresses LacZ only in *nautilus*-positive cells that can be chased into most of the embryonic muscle groups: *lacZ* expression was eliminated with no effect on the muscle pattern. Likewise, early *DMEF2* expression is not affected in embryos injected with *nautilus* dsRNA or induced for ricin expression (data not shown).

It was imperative that we established the specificity of the RNA interference approach in *Drosophila*. To do this we prepared a selection of dsRNAs for injection representing genes expressed maternally and zygotically in the embryo and, much later, in the adult eye. In practically every instance the phenotype observed from the injection of dsRNA was comparable to the original mutant, demonstrating the specificity of the procedure. This analysis underscores the utility of this approach. The function of any gene or combination of genes in *Drosophila* development, particularly in the embryo, can be disrupted simply by injecting dsRNAs representing all or a portion of the coding region of the gene or genes in question. The shortest piece of dsRNA we injected was roughly 200 bp, representing the bHLH region of *nautilus*. Shorter dsRNA fragments may work as well. RNA interference analysis of several genes in *Drosophila* as well as *nautilus*, combined with the fact that *nautilus* is expressed in roughly 30 muscle precursor cells in each hemisegment that are eventually incorporated into every somatic muscle of the embryo (9), allows us to conclude that *nautilus* does play a crucial role in defining the muscle founder cells and that *nautilus* gene function is essential for normal myogenesis in *Drosophila*.

There are several possible mechanisms for RNA interference involving catalytic degradation, interference with chromatin structure and/or transcription, or interaction between RNA and the genome. Whatever the mechanism, it does not involve promoter or intronic sequences. As mentioned previ-

ously, the fact that the endogenous *mex3* transcript can be degraded in the *C. elegans* embryo suggests the mechanism operates posttranscriptionally, so an enzymatic process is most likely involved. However, the exact mechanism underlying RNA interference is not understood at the present time.

Note Added in Proof. While my paper was in press, similar results with dsRNA-mediated genetic interference in *Drosophila* also were reported by Kennerdell and Carthew.

We thank Ward Odenwald for help with the filleted embryo preparations.

1. Rushton, E., Drysdale, R., Abmayr, S. M., Michelson, A. M. & Bate, M. (1995) *Development* **121**, 1979–1988.
2. Bate, M. (1990) *Development* **110**, 791–804.
3. Ho, R. K., Ball, E. E. & Goodman, C. S. (1983) *Nature (London)* **301**, 66–69.
4. Keller, C. A., Grill, M. A. & Abmayr, S. M. (1998) *Dev. Biol.* **202**, 153–156.
5. Abmayr, S. M., Erickson, M. S. & Bour, B. A. (1995) *Trends Genet.* **11**, 153–159.
6. Abmayr, S. M. & Keller, C. A. (1998) *Curr. Top. Dev. Biol.* **38**, 35–80.
7. Hidalgo, A., Urban, J. & Brand, A. H. (1995) *Development* **121**, 3703–3712.
8. Hidalgo, A. & Brand, A. H. (1997) *Development* **124**, 3253–3262.
9. Paterson, B. M., Walldorf, U., Eldridge, J., Dubendorfer, A., Frasch, M. & Gehring, W. J. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 3782–3786.
10. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E. & Mello, C. C. (1998) *Nature (London)* **391**, 806–811.
11. Thisse, B., Stoetzel, C., Gorostiza-Thisse, C. & Perrin-Schmitt, F. (1988) *EMBO J.* **7**, 2175–2183.
12. Caudy, M., Grell, E. H., Dambly-Chaudiere, C., Ghysen, A., Jan, L. Y. & Jan, Y. N. (1988) *Genes Dev.* **2**, 843–852.
13. Cronmiller, C., Schedl, P. & Cline, T. W. (1988) *Genes Dev.* **2**, 1666–1676.
14. Kassis, J. A., Desplan, C., Wright, D. K. & O'Farrell, P. H. (1989) *Mol. Cell. Biol.* **9**, 4304–4311.
15. Dohrmann, C., Azpiazu, N. & Frasch, M. (1990) *Genes Dev.* **4**, 2098–2111.
16. Lilly, B., Galewsky, S., Firulli, A. B., Schulz, R. A. & Olson, E. N. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 5662–5666.
17. Pirrotta, V. (1988) *Biotechnology* **10**, 437–456.
18. Brand, A. H. & Perrimon, N. (1993) *Development* **118**, 401–415.
19. Buff, E., Carmena, A., Gisselbrecht, S., Jimenez, F. & Michelson, A. M. (1998) *Development* **125**, 2075–2086.
20. Chen, L., Krause, M., Sepanski, M. & Fire, A. (1994) *Development* **120**, 1631–1641.
21. Rudnicki, M. A. & Jaenisch, R. (1995) *BioEssays* **17**, 203–209.
22. Keller, C. A., Erickson, M. S. & Abmayr, S. M. (1997) *Dev. Biol.* **181**, 197–212.
23. Lilly, B., Zhao, B., Ranganayakulu, G., Paterson, B. M., Schulz, R. A. & Olson, E. N. (1995) *Science* **267**, 688–693.
24. Weintraub, H. (1993) *Cell* **75**, 1241–1244.
25. Kennerdell, J. R. & Carthew, R. W. (1998) *Cell* **95**, 1017–1026.